Sequent Scientific has launched Halofusol 0.5 mg/ml Oral Solution for Calves in 19 European countries. The product had recently received approval from the European Medicines Agency (EMA) through its Spanish subsidiary Laboratorios Karizoo, S.A. The product was developed at SeQuent’s R&D centre at Barcelona, Spain & will be manufactured in Spain. The approval follows the recent approval of Tulathromycin, both of which were approved within 12 months of filing, reflecting of SeQuent’s growing strength in product development for the regulated markets.
Halofusol offers superior value for farmers with user-friendly and cost-effective drug delivery system. Halofusol is an oral antiprotozoal solution for the prevention and reduction of diarrhoea in new-born calves, diagnosed with Cryptosporidium parvum and is a generic version of Halocur (Innovator: Merck Animal Health) with market size of Euro10 million. The company is also planning to extend the launch to other geographies.
Sequent Scientific is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services, CRAMS and specialty chemicals. Sequent is the world's largest producer of Anthelmintics and by far the strongest player in the Veterinary API business.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1483.75 |
Dr. Reddys Lab | 5947.30 |
Cipla | 1347.70 |
Zydus Lifesciences | 958.90 |
Lupin | 1580.00 |
View more.. |